@article{c246612cf16e4207904ef1c26a96c531,
title = "Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia",
keywords = "blinatumomab, antineoplastic agent, bispecific antibody, acute lymphoblastic leukemia, aging, Australia, blast cell, blood cell count, Canada, cancer chemotherapy, cancer combination chemotherapy, cancer prognosis, chromosome 11q, comparative study, drug efficacy, Europe, follow up, hematopoietic stem cell transplantation, human, intensive care, Letter, leukemia relapse, North America, overall survival, phase 1 clinical trial (topic), phase 2 clinical trial (topic), Philadelphia chromosome negative cell, priority journal, risk factor, salvage therapy, sample size, sex ratio, therapy effect, treatment outcome, United States, adolescent, child, female, genetics, male, Philadelphia 1 chromosome, preschool child, recurrent disease, Adolescent, Antibodies, Bispecific, Antineoplastic Agents, Child, Child, Preschool, Female, Humans, Male, Philadelphia Chromosome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Recurrence",
author = "F. Locatelli and J.A. Whitlock and C. Peters and C. Chen-Santel and V. Chia and R.M. Dennis and K.M. Heym and A.J. Katz and M.A. Kelsh and R. Sposto and H. Tu and C.A. Tuglus and A. Verma and L. Vinti and J.J. Wilkes and N. Zubarovskaja and G. Zugmaier and {von Stackelberg}, A. and W. Sun",
note = "Cited By :3 Export Date: 19 March 2021 CODEN: LEUKE Correspondence Address: Locatelli, F.; Department of Pediatric Hematology/Oncology and of Cell and Gene Therapy, Italy; email: franco.locatelli@opbg.net",
year = "2020",
doi = "10.1038/s41375-020-0770-8",
language = "English",
volume = "34",
pages = "2473--2478",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Springer Nature",
number = "9",
}